Bacteria and the growing threat of multidrug resistance for invasive cardiac interventions

Pierce, Grant N.; Resch, Craig; Mourin, Muntahi; Dibrov, Pavel; Dibrov, Elena; Ravandi, Amir

doi:10.31083/j.rcm2301015

Cited by 13 publications

(14 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular patients are also at high risk of infections because of invasive procedures used, including transplantation, congenital heart disease, and coronary artery bypass grafts. Staphylococcus aureus , particularly MRSA and Acinetobacter baumannii, are among the common bacteria associated with cardiovascular patients [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Bacterial Infections among Patients with Chronic Diseases at a Tertiary Care Hospital in Saudi Arabia

et al. 2022

View full text Add to dashboard Cite

Infections caused by multi-drug-resistant bacteria in patients with chronic diseases have been associated with high mortality and morbidity. While few reports have evaluated bacterial infections in multiple chronic disease patients, the focus of the current study was to investigate the prevalence of bacterial infections and the susceptibility profiles of causative strains among various groups of patients suffering from chronic diseases. Microbiological reports of patients suffering from cancer, diabetes mellitus, cardiovascular diseases, kidney diseases, and skin burns were retrospectively collected from a tertiary hospital in Saudi Arabia. Approximately 54.2% of recruited patients were males, and positive urine was the most prevalent specimen associated with kidney disease patients (25%). Escherichia coli isolates were predominant among cardiovascular, kidney, and cancer patients. Staphylococcus aureus was commonly detected in diabetics and those with burns. Although resistance patterns varied based on the type of specimens and underlying diseases, Escherichia coli showed limited resistance to colistin, carbapenems, and tigecycline, while S. aureus demonstrated susceptibility to ciprofloxacin, gentamicin, and rifampin. These observations are crucial for clinicians and policymakers to ensure effective treatment plans and improve outcomes in these patients with comorbidity.

show abstract

Section: Introductionmentioning

confidence: 99%

Bacterial Infections among Patients with Chronic Diseases at a Tertiary Care Hospital in Saudi Arabia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Outbreaks of bacterial infection, usually associated with multidrug resistance, are increasingly reported and may soon be responsible for millions of deaths per year [ 51 , 52 , 53 ]. Furthermore, the increase in hard-to-treat or untreatable bacteria also threatens medical procedures such as surgery, care for premature infants, organ transplants, treatment of numerous chronic diseases, including cancer, and also multiple dental procedures [ 13 , 54 , 55 , 56 ]. The impact of the drug resistance crisis is such that it was included within the group of the top ten global health threats [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions

et al. 2023

View full text Add to dashboard Cite

Plazomicin is a recent U.S. Food and Drug Administration (FDA)-approved semisynthetic aminoglycoside. Its structure consists of a sisomicin scaffold modified by adding a 2(S)-hydroxy aminobutyryl group at the N1 position and a hydroxyethyl substituent at the 6′ position. These substitutions produced a molecule refractory to most aminoglycoside-modifying enzymes. The main enzyme within this group that recognizes plazomicin as substrate is the aminoglycoside 2′-N-acetyltransferase type Ia [AAC(2′)-Ia], which reduces the antibiotic’s potency. Designing formulations that combine an antimicrobial with an inhibitor of resistance is a recognized strategy to extend the useful life of existing antibiotics. We have recently found that several metal ions inhibit the enzymatic inactivation of numerous aminoglycosides mediated by the aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6′)-Ib]. In particular, Ag+, which also enhances the effect of aminoglycosides by other mechanisms, is very effective in interfering with AAC(6′)-Ib-mediated resistance to amikacin. Here we report that silver acetate is a potent inhibitor of AAC(2′)-Ia-mediated acetylation of plazomicin in vitro, and it reduces resistance levels of Escherichia coli carrying aac(2′)-Ia. The resistance reversion assays produced equivalent results when the structural gene was expressed under the control of the natural or the blaTEM-1 promoters. The antibiotic effect of plazomicin in combination with silver was bactericidal, and the mix did not show significant toxicity to human embryonic kidney 293 (HEK293) cells.

show abstract

“…Outbreaks of bacterial infection, usually associated with multidrug resistance, are increasingly reported and may soon be responsible for millions of deaths per year [35][36][37]. Furthermore, the increase in hard-to-treat or untreatable bacteria also threatens medical procedures like surgery, cancer treatment and other chronic diseases, organ transplants, dental work, and care for premature infants [13,[38][39][40]. The impact of the drug resistance crisis is such that it was listed as one of the top ten global health threats [41].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions

Ngo¹,

Magaña²,

Tran³

et al. 2023

Preprint

View full text Add to dashboard Cite

Plazomicin is a recently U.S. Food and Drug Administration (FDA)-approved semisynthetic aminoglycoside. Its structure consists of a sisomicin scaffold modified by adding a 2(S)-hydroxy aminobutyryl group at the N1 position and a hydroxyethyl substituent at the 6′ position. These substitutions produced a molecule refractory to most aminoglycoside-modifying enzymes. The main enzyme within this group that recognizes plazomicin as substrate is the aminoglycoside 2′-N-acetyltransferase type Ia [AAC(2′)-Ia], which reduces the antibiotic’s potency. Designing formulations that combine an antimicrobial with an inhibitor of resistance is a recognized strategy to extend the useful life of existing antibiotics. We have recently found that several metal ions inhibit acetylation of numerous aminoglycosides catalyzed by the aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6′)-Ib]. In particular, Ag1+, which also enhances the effect of aminoglycosides by other mechanisms, is very effective in interfering with AAC(6′)-Ib-mediated resistance to amikacin. Here we report that silver acetate is a potent inhibitor of AAC(2′)-Ia-mediated acetylation of plazomicin in vitro, and it reduces resistance levels of Escherichia coli carrying aac(2′)-Ia. The resistance reversion assays produced equivalent results when the structural gene was expressed under the control of the natural or the blaTEM-1 promoters. The antibiotic effect of plazomicin in combination with silver was bactericidal, and the mix did not show significant toxicity to human embryonic kidney 293 (HEK293) cells.

show abstract

Bacteria and the growing threat of multidrug resistance for invasive cardiac interventions

Cited by 13 publications

References 66 publications

Bacterial Infections among Patients with Chronic Diseases at a Tertiary Care Hospital in Saudi Arabia

Bacterial Infections among Patients with Chronic Diseases at a Tertiary Care Hospital in Saudi Arabia

Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions

Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions

Contact Info

Product

Resources

About